Free press releases distribution network?

Agency / Source: Genentech, Inc.

Check Ads Availability|e-mail Article
This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



FDA Approves Genentech’s Tecentriq in Combination with Avastin and Chemotherapy - FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer - Tecentriq.com / Genentech-Access.com
FDA Approves Genentech’s Tecentriq in Combination with Avastin and Chemotherapy

 

PRTODAY - Newswire & PRZOOM/ - South San Francisco, CA, United States, 01/07/2019 - FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer - Tecentriq.com / Genentech-Access.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Approval based on survival benefit of Tecentriq, in combination with Avastin, paclitaxel and carboplatin (chemotherapy), in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations compared to Avastin plus chemotherapy

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

“This Tecentriq regimen has demonstrated a significant survival benefit in the initial treatment of metastatic non-squamous non-small cell lung cancer,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “Today’s approval supports our combination approach for Tecentriq in lung cancer and our vision to develop medicines that improve outcomes for patients with this complex disease.”

This approval is based on results from the Phase III IMpower150 study, which showed that Tecentriq in combination with Avastin and chemotherapy helped people live significantly longer compared to Avastin and chemotherapy (median overall survival [OS] = 19.2 versus 14.7 months; hazard ratio [HR] = 0.78; 95 percent CI: 0.64-0.96; p=0.016) in the intention-to-treat wild-type (ITT-WT) population. The safety profile of the Tecentriq combination was consistent with that observed in previous studies.

Genentech is working with the FDA on postmarketing commitments (PMCs) to better understand and characterize the potential effects of Tecentriq-related anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) across all of our studies. An analysis of ADAs in the IMpower150 study showed no impact on the efficacy of Tecentriq.

Tecentriq (tecentriq.com) is also approved by the FDA to treat people with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK genetic alterations.

For those who qualify, Genentech offers patient assistance programs for people taking Tecentriq through Genentech Access Solutions. Doctors can contact Genentech Access Solutions at (866) 422-2377. More information is also available at Genentech-Access.com/.

About the IMpower150 study
IMpower150 is a multicenter, open-label, randomized, controlled Phase III study evaluating the efficacy and safety of Tecentriq in combination with chemotherapy (carboplatin and paclitaxel) with or without Avastin in people with Stage IV or recurrent metastatic non-squamous NSCLC who had not been treated with chemotherapy for their advanced disease. It enrolled 1,202 people, of whom 1,045 were in the ITT-WT subpopulation, which excluded those people with EGFR and ALK mutations. People were randomized (1:1:1) to receive:

• Tecentriq plus carboplatin and paclitaxel (Arm A), or
• Tecentriq and Avastin plus carboplatin and paclitaxel (Arm B), or
• Avastin plus carboplatin and paclitaxel (Arm C, control arm).

The co-primary endpoints comparing Arms B and C were progression-free survival (PFS) as determined by the independent review facility (IRF) using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) and OS and assessed in the ITT-WT subpopulation. Key secondary endpoints included IRF-assessed PFS, OS and safety in the ITT population.

A summary of the ITT-WT data from the IMpower150 study that support this approval is included below.

Tecentriq in combination with Avastin and chemotherapy helped people live significantly longer compared to Avastin and chemotherapy (median OS=19.2 versus 14.7 months; HR=0.78, 95 percent CI: 0.64-0.96; p=0.016).
In addition, Tecentriq in combination with Avastin and chemotherapy reduced risk of disease worsening or death (PFS) by 29 percent compared to Avastin and chemotherapy (HR=0.71, 95 percent CI: 0.59-0.85, p=0.0002).
Tecentriq in combination with Avastin and chemotherapy shrank tumors (overall response rate; ORR) in 55 percent of people (95 percent CI: 49-60) compared to 42 percent of people (95 percent CI: 37-48) on Avastin and chemotherapy.
4 percent of people receiving Tecentriq in combination with Avastin and chemotherapy experienced a complete response (CR), and 51 percent of people experienced a partial response (PR).
The median duration of response (DoR) for people receiving Tecentriq in combination with Avastin and chemotherapy was 10.8 months (95 percent CI: 8.4-13.9) compared to 6.5 months (95 percent CI: 5.6-7.6) for people on Avastin and chemotherapy.
The most common adverse reactions (≥20 percent) in people receiving Tecentriq in combination with Avastin and chemotherapy were fatigue and lack of energy (asthenia; 50 percent), hair loss (alopecia; 48 percent), nausea (39 percent), diarrhea (32 percent), constipation (30 percent), decreased appetite (29 percent), joint pain (arthralgia; 26 percent), hypertension (25 percent) and pain from nerve damage (peripheral neuropathy; 24 percent).

About lung cancer
According to the American Cancer Society, it is estimated that more than 234,000 Americans will be diagnosed with lung cancer in 2018, and NSCLC accounts for 85 percent of all lung cancers. It is estimated that approximately 60 percent of lung cancer diagnoses in the United States are made when the disease is in the advanced stages.

About Genentech Access Solutions
Access Solutions (Genentech-Access.com) is part of Genentech’s commitment to helping people access the Genentech medicines they are prescribed, regardless of their ability to pay. The team of in-house specialists at Access Solutions is dedicated to helping people navigate the access and reimbursement process, and to providing assistance to eligible patients in the United States who are uninsured or cannot afford the out-of-pocket costs for their medicine. To date, the team has helped more than 1.5 million patients access the medicines they need. Please contact Access Solutions (866) 4ACCESS/866-422-2377.

About Tecentriq® (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumor cells and tumor-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.

About Avastin® (bevacizumab)
Avastin is a prescription-only medicine that is a solution for intravenous infusion. It is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the tumor blood supply by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. The tumor blood supply is thought to be critical to a tumor's ability to grow and spread in the body (metastasize).

Tecentriq U.S. Indication (pronounced ‘tē-SEN-trik’)

Tecentriq is a prescription medicine used to treat:

A type of bladder and urinary tract cancer called urothelial carcinoma.

• Tecentriq may be used when your bladder cancer:

has spread or cannot be removed by surgery, and if you have any one of the following conditions:
- you are not able to take chemotherapy that contains a medicine called cisplatin, and your doctor has tested your cancer and found high levels of a specific protein on your cancer called programmed death-ligand 1 (PD-L1); or
- you are not able to take chemotherapy that contains any platinum regardless of the levels of PD-L1 on your cancer; or
- you have tried chemotherapy that contains platinum, and it did not work or is no longer working.

The approval of Tecentriq in these patients is based on a study that measured response rate and duration of response. There is an ongoing study to confirm clinical benefit.

A type of lung cancer called non-small cell lung cancer (NSCLC).

• Tecentriq may be used with bevacizumab and the chemotherapy medicines carboplatin and paclitaxel as your first treatment when your lung cancer:
- has spread or grown; and
- is a type of lung cancer called non-squamous NSCLC;
- your tumor does not have an abnormal “EGFR” or “ALK” gene.

• Tecentriq may be used when your lung cancer:
- has spread or grown; and
- you have tried chemotherapy that contains platinum, and it did not work or is no longer working;
- If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

It is not known if Tecentriq is safe and effective in children.

Important Safety Information

What is the most important information about Tecentriq?

Tecentriq can cause the immune system to attack normal organs and tissues and can affect the way they work. These problems can sometimes become serious or life threatening and can lead to death.

Patients should call or see their healthcare provider right away if they get any symptoms of the following problems or these symptoms get worse.

Tecentriq can cause serious side effects, including:

• Lung problems (pneumonitis) signs and symptoms of pneumonitis may include new or worsening cough, shortness of breath, and chest pain;
• Liver problems (hepatitis) signs and symptoms of hepatitis may include yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on the right side of your stomach area (abdomen), drowsiness, dark urine (tea colored), bleeding or bruising more easily than normal, and feeling less hungry than usual;
• Intestinal problems (colitis) signs and symptoms of colitis may include diarrhea (loose stools) or more bowel movements than usual, blood or mucus in your stools or dark, tarry, sticky stools, and severe stomach area (abdomen) pain or tenderness;
• Hormone gland problems (especially the thyroid, adrenal glands, pancreas, and pituitary) signs and symptoms that your hormone glands are not working properly may include headaches that will not go away or unusual headaches, extreme tiredness, weight gain or weight loss, dizziness or fainting, feeling more hungry or thirsty than usual, hair loss, changes in mood or behavior (such as decreased sex drive, irritability, or forgetfulness), feeling cold, constipation, your voice gets deeper, urinating more often than usual, nausea or vomiting, and stomach area (abdomen) pain;
• Problems in other organs signs and symptoms may include severe muscle weakness, numbness or tingling in hands or feet, confusion, blurry vision, double vision, or other vision problems, changes in mood or behavior, extreme sensitivity to light, neck stiffness, eye pain or redness, skin blisters or peeling, chest pain, irregular heartbeat, shortness of breath, or swelling of the ankles
• Severe infections signs and symptoms of infection may include fever, cough, flu-like symptoms, pain when urinating, and frequent urination or back pain;
• Severe infusion reactions signs and symptoms of infusion reactions may include chills or shaking, itching or rash, flushing, shortness of breath or wheezing, swelling of your face or lips, dizziness, fever, feeling like passing out, and back or neck pain.

Getting medical treatment right away may help keep these problems from becoming more serious. A healthcare provider may treat patients with corticosteroid or hormone replacement medicines. A healthcare provider may delay or completely stop treatment with Tecentriq if patients have severe side effects.

Before receiving Tecentriq, patients should tell their healthcare provider about all of their medical conditions, including if they:

• have immune system problems (such as Crohn’s disease, ulcerative colitis, or lupus); have had an organ transplant; have lung or breathing problems; have liver problems; have a condition that affects the nervous system (such as myasthenia gravis or Guillain-Barre syndrome); or are being treated for an infection;
• are pregnant or plan to become pregnant. Tecentriq can harm an unborn baby. Patients should tell their healthcare provider right away if they become pregnant or think they may be pregnant during treatment with Tecentriq. Females who are able to become pregnant:
- A healthcare provider should do a pregnancy test before they start treatment with Tecentriq;
- They should use an effective method of birth control during their treatment and for at least 5 months after the last dose of Tecentriq.
• are breastfeeding or plan to breastfeed. It is not known if Tecentriq passes into the breast milk. Patients should not breastfeed during treatment and for at least 5 months after the last dose of Tecentriq.

Patients should tell their healthcare provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects of Tecentriq when used alone include:

• feeling tired;
• nausea;
• constipation;
• cough;
• shortness of breath.
• decreased appetite

The most common side effects of Tecentriq when used with bevacizumab, paclitaxel, and carboplatin include:

• feeling tired or weak;
• hair loss;
• nausea;
• diarrhea;
• constipation;
• decreased appetite;
• joint pain;
• high blood pressure;
• tingling or numbness in hands and feet.

Tecentriq may cause fertility problems in females, which may affect the ability to have children. Patients should talk to their healthcare provider if they have concerns about fertility.

These are not all the possible side effects of Tecentriq. Patients should ask their healthcare provider or pharmacist for more information. Patients should call their doctor for medical advice about side effects.

Report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Report side effects to Genentech at 1-888-835-2555.

Please visit Tecentriq.com for the Tecentriq full Prescribing Information for additional Important Safety Information.

Avastin Indications

• Metastatic colorectal cancer (mCRC) for first- or second-line treatment in combination with intravenous 5-fluorouracil based chemotherapy. It is also approved to treat mCRC for second-line treatment, when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy, after cancer progresses following a first-line treatment that includes Avastin.
- Avastin is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body
• Advanced nonsquamous non small cell lung cancer (NSCLC) in combination with carboplatin and paclitaxel, in people who have not received chemotherapy for their advanced disease
• Metastatic kidney cancer (mRCC) when used with interferon alfa
• Glioblastoma (GBM) in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM)
• Advanced cervical cancer (CC) in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix
• Ovarian cancer (OC). Avastin, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.

Avastin in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (prOC) in women who received no more than two prior chemotherapy treatments.

Avastin, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer (psOC)

Possible serious side effects
Everyone reacts differently to Avastin therapy. So, it’s important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Their doctor will stop treatment if any serious side effects occur. Patients should contact their health care team if there are any signs of these side effects.

Most serious side effects (not common, but sometimes fatal):

• GI perforation. A hole that develops in the stomach or intestine. Symptoms include pain in the abdomen, nausea, vomiting, constipation, or fever
• Wounds that don’t heal. A cut made during surgery can be slow to heal or may not fully heal. Avastin should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed
• Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If a patient has recently coughed up blood or had serious bleeding, they should be sure to tell their doctor

Other possible serious side effects

• Abnormal passage in the body. This type of passage known as a fistula is an irregular connection from one part of the body to another and can sometimes be fatal
• Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on Avastin and after stopping treatment
• Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal
• Infusion reactions. These were uncommon with the first dose (less than 3% of patients). 0.2% of patients had severe reactions. Infusion reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. The patient’s doctor or nurse will monitor for signs of infusion reactions
• Severe stroke or heart problems. These may include blood clots, mini-stroke, heart attack, chest pain, and the heart may become too weak to pump blood to other parts of the body (congestive heart failure). These can sometimes be fatal
• Nervous system and vision problems. Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

Side effects seen most often

In clinical studies across different types of cancer, some patients experienced the following side effects:

• High blood pressure
• Too much protein in the urine
• Nosebleeds
• Rectal bleeding
• Back pain
• Headache
• Taste change
• Dry skin
• Inflammation of the skin
• Inflammation of the nose
• Watery eyes.

Avastin (avastin.com) is not for everyone

Patients should talk to their doctor if they are:

• Undergoing surgery. Avastin should not be used for 28 days before or after surgery and until surgical wounds are fully healed;
• Pregnant or think they are pregnant. Data have shown that Avastin may harm a woman’s unborn baby. Birth control should be used while patients are on Avastin. If Avastin is stopped, patients should keep using birth control for 6 months before trying to become pregnant;
• Planning to become pregnant. Taking Avastin could cause a woman’s ovaries to stop working and may impair her ability to have children;
• Breastfeeding. Breastfeeding while on Avastin may harm the baby and is therefore not recommended during and for 6 months after taking Avastin.

Patients should talk with their doctor if they have any questions about their condition or treatment.

Report side effects to the FDA at (800) FDA-1088 or fda.gov/medwatch. Report side effects to Genentech at 888-835-2555.

About Genentech in Personalized Cancer Immunotherapy
For more than 30 years, Genentech (gene.com/cancer-immunotherapy) has been developing medicines with the goal to redefine treatment in oncology. Today, we’re investing more than ever to bring personalized cancer immunotherapy (PCI) to people with cancer. The goal of PCI is to provide each person with a treatment tailored to harness his or her own immune system to fight cancer. Genentech is studying more than 20 investigational medicines, 10 of which are in clinical trials. In every study we are evaluating biomarkers to identify which people may be appropriate candidates for our medicines.

About Genentech in Lung Cancer
Lung cancer is a major area of focus and investment for Genentech, and we are committed to developing new approaches, medicines and tests that can help people with this deadly disease. Our goal is to provide an effective treatment option for every person diagnosed with lung cancer. We currently have four approved medicines to treat certain kinds of lung cancer and more than 10 medicines being developed to target the most common genetic drivers of lung cancer or to boost the immune system to combat the disease.

About Genentech
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit gene.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Genentech, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRTODAY - Newswire Distribution Service Visibility Checker

 

Distribution / Indexing: [+] [Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


FDA Approves Genentech’s Tecentriq in Combination with Avastin and Chemotherapy

Non-featured company website links are shown on a random basis
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRTODAY - Newswire Distribution Service and LINK as the source.
 
  For more information, please visit:
Links are available on a random basis for non premium members
Genentech’s Tecentriq |
Contact: Press Office - Gene.com 
650-467-6800 press[.]gene.com
 
Newswire Today - PRZOOM disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.

Pharma/BioTech/Nutrition via RSS
AddThis press release: FDA Approves Genentech’s Tecentriq in Combination with Avastin and ChemotherapyAdd Pharma/BioTech/Nutrition News to My MSNAdd Pharma/BioTech/Nutrition News to My Yahoo!Add NewswireToday Pharma/BioTech/Nutrition Press Release Headline News to Your Google homepage or Google ReaderAdd NewswireToday - PRZOOM Headline News to FeedBurner

This article was published free of charge. Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read More Articles From Genentech, Inc. / Company Profile



Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

STEMCELL Technologies Launches mTeSR™ Plus - A Next-Generation Culture System for Human ES and iPS Cell Maintenance
Sartorius Stedim Biotech Launches Services for Characterization of New Biological Entities (NBE)
Sartorius Stedim Biotech Introduces BIOSTAT® RM TX with Flexsafe® RM TX for Producing Consistent Quality Cellular Products
Sartorius to Demonstrate Special Data Analysis At Night of Knowledge Event Series
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin)
Cell Therapy Market to Grow Beyond Oncology As Big Pharma Expands Investments Finds Frost & Sullivan
Bioquark, Inc. and Ectocrine Technologies, LLC to Collaborate on Mosquito-Derived Health Products
BTG and OMNY Partner to Improve Treatment of Snake Bite Victims
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial of Cabozantinib in Combination with Atezolizumab Versus Sorafenib
Ipsen and 3BP Announce First Patient Dosed in Phase I/II study for First-in-Class Radionuclide (IPN01087)

Reserve This Permanent SPACE

Your LOGO permanently HERE on PRTODAY - Newswire Distribution Service most visited Page start at $295 per month

 
Sponsored Links


Visit  Limelon Advertising, Co.

Visit  BizJobs.com

Visit  JobsWare.com





Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



 
  ©2014 PRTODAY — Limelon Advertising, Co.
Home | About PRTODAY | Advertise | Contact | Investors | Sitemap | FRANCAIS
newswire, PR free press releases distribution magazines engine news alert newsroom press room breaking news public relations articles company news alerts blogsIt younews.me newswiredistribution ezine younews.asia bizentrepreneur biznewstoday digital business report news market search pr firms pr agencies business reports newswire today distri- bution investor relation successful internet entrepreneur free newswire distribution prtoday freenewswiredistribution.com asianewstoday bizwiretoday newswire pr today
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)